Ovarian Screening vs Control: Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.00549	0.00476	0.00633	wilson	ClinicalTrials.gov
Risk in group 2	0.00292	0.0024	0.00354	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	0.00257	0.00161	0.00356	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	1.88	1.48	2.4	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	1.89	1.48	2.41	log	ClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on Ovarian Screening than on Control	389	281	621	from the risk difference interval	ClinicalTrials.gov

Groups 2

Group 2 names the comparator: control.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	Ovarian Screening	Participants undergo blood sample collection for CA-125 analysis at baseline annually for 5 years. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years.	188	34,253	OG001	ClinicalTrials.gov
Group 2	Control	Participants receive standard medical care.	100	34,304	OG000	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	PRIMARY	ClinicalTrials.gov
Title	Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)	ClinicalTrials.gov
Description	Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.	ClinicalTrials.gov
Time frame	Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.	ClinicalTrials.gov
Population		ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)	ClinicalTrials.gov
NCT number	NCT01696994	ClinicalTrials.gov
Phases	NA	ClinicalTrials.gov
Conditions	Ovarian Carcinoma, Ovarian Germ Cell Tumor	ClinicalTrials.gov
Interventions	Laboratory Biomarker Analysis, Screening Questionnaire Administration, Ultrasound Imaging	ClinicalTrials.gov
Lead sponsor	National Cancer Institute (NCI)	ClinicalTrials.gov
Results first posted	2014-12-12	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT01696994?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.